| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 8 | 2019 | 81 | 3.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 30 | 2022 | 1085 | 3.200 |
Why?
|
| Diabetes Mellitus | 15 | 2020 | 694 | 2.420 |
Why?
|
| Pediatric Obesity | 5 | 2022 | 92 | 2.370 |
Why?
|
| Cardiovascular Diseases | 15 | 2022 | 938 | 2.000 |
Why?
|
| Diabetes Mellitus, Type 1 | 14 | 2022 | 529 | 1.880 |
Why?
|
| Veterans | 16 | 2022 | 904 | 1.800 |
Why?
|
| Body Mass Index | 17 | 2022 | 866 | 1.780 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2022 | 28 | 1.700 |
Why?
|
| Metabolic Syndrome | 11 | 2018 | 191 | 1.670 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2022 | 154 | 1.570 |
Why?
|
| Pregnancy | 20 | 2022 | 2334 | 1.560 |
Why?
|
| Nutrition Surveys | 6 | 2020 | 204 | 1.530 |
Why?
|
| Female | 116 | 2022 | 38021 | 1.530 |
Why?
|
| Health Status Disparities | 6 | 2022 | 326 | 1.470 |
Why?
|
| Pregnancy in Diabetics | 4 | 2019 | 70 | 1.470 |
Why?
|
| Heart Failure | 5 | 2021 | 1179 | 1.440 |
Why?
|
| Birth Weight | 5 | 2021 | 186 | 1.420 |
Why?
|
| Mexican Americans | 13 | 2014 | 30 | 1.410 |
Why?
|
| Cohort Studies | 31 | 2022 | 2356 | 1.360 |
Why?
|
| Diabetic Nephropathies | 6 | 2022 | 161 | 1.360 |
Why?
|
| Humans | 145 | 2023 | 68549 | 1.330 |
Why?
|
| Breast Feeding | 2 | 2021 | 159 | 1.300 |
Why?
|
| Male | 96 | 2022 | 37283 | 1.210 |
Why?
|
| Delivery of Health Care | 5 | 2019 | 445 | 1.200 |
Why?
|
| Risk Factors | 39 | 2022 | 5720 | 1.200 |
Why?
|
| United States | 40 | 2022 | 7338 | 1.160 |
Why?
|
| Healthcare Disparities | 7 | 2022 | 378 | 1.140 |
Why?
|
| Middle Aged | 73 | 2021 | 21119 | 1.130 |
Why?
|
| Adult | 64 | 2023 | 21379 | 1.110 |
Why?
|
| Weight Gain | 4 | 2022 | 135 | 1.090 |
Why?
|
| Prevalence | 22 | 2019 | 1609 | 1.080 |
Why?
|
| United States Department of Veterans Affairs | 8 | 2020 | 307 | 1.070 |
Why?
|
| Mortality | 3 | 2018 | 162 | 1.050 |
Why?
|
| Hospitalization | 5 | 2023 | 977 | 1.030 |
Why?
|
| Lipoproteins, LDL | 10 | 2022 | 343 | 1.030 |
Why?
|
| Child | 22 | 2022 | 6401 | 1.030 |
Why?
|
| Environmental Pollutants | 3 | 2022 | 180 | 1.030 |
Why?
|
| Obesity | 16 | 2022 | 1074 | 1.020 |
Why?
|
| Diet | 5 | 2020 | 514 | 0.990 |
Why?
|
| Biomarkers | 15 | 2019 | 1593 | 0.980 |
Why?
|
| Hypertension | 10 | 2021 | 1533 | 0.960 |
Why?
|
| Blood Glucose | 14 | 2016 | 631 | 0.960 |
Why?
|
| Emergency Service, Hospital | 4 | 2023 | 711 | 0.900 |
Why?
|
| Energy Intake | 3 | 2020 | 123 | 0.900 |
Why?
|
| Young Adult | 22 | 2021 | 5710 | 0.890 |
Why?
|
| Atherosclerosis | 3 | 2015 | 204 | 0.890 |
Why?
|
| Residence Characteristics | 3 | 2020 | 252 | 0.880 |
Why?
|
| Retrospective Studies | 25 | 2022 | 7268 | 0.880 |
Why?
|
| Overweight | 4 | 2021 | 186 | 0.870 |
Why?
|
| Proportional Hazards Models | 15 | 2018 | 791 | 0.870 |
Why?
|
| Diabetic Angiopathies | 5 | 2019 | 203 | 0.860 |
Why?
|
| Medication Adherence | 6 | 2020 | 335 | 0.860 |
Why?
|
| Pre-Eclampsia | 2 | 2022 | 202 | 0.850 |
Why?
|
| Glycation End Products, Advanced | 7 | 2019 | 125 | 0.830 |
Why?
|
| Adolescent | 26 | 2022 | 8904 | 0.820 |
Why?
|
| Sweetening Agents | 2 | 2020 | 23 | 0.820 |
Why?
|
| Aged | 40 | 2022 | 14842 | 0.800 |
Why?
|
| Metabolic Diseases | 2 | 2018 | 37 | 0.800 |
Why?
|
| Eclampsia | 1 | 2021 | 16 | 0.790 |
Why?
|
| Feeding Behavior | 2 | 2020 | 224 | 0.790 |
Why?
|
| Albuminuria | 9 | 2019 | 171 | 0.770 |
Why?
|
| Alkanesulfonic Acids | 1 | 2021 | 54 | 0.760 |
Why?
|
| Child, Preschool | 11 | 2022 | 3187 | 0.760 |
Why?
|
| Prehypertension | 1 | 2021 | 40 | 0.760 |
Why?
|
| Blood Pressure | 9 | 2021 | 1449 | 0.750 |
Why?
|
| Fluorocarbons | 1 | 2021 | 82 | 0.730 |
Why?
|
| Rural Population | 4 | 2018 | 397 | 0.730 |
Why?
|
| Coronary Artery Disease | 3 | 2021 | 696 | 0.720 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2017 | 444 | 0.710 |
Why?
|
| Odds Ratio | 12 | 2019 | 880 | 0.710 |
Why?
|
| Maternal Exposure | 3 | 2022 | 75 | 0.700 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2020 | 37 | 0.700 |
Why?
|
| Disease Progression | 11 | 2019 | 1037 | 0.690 |
Why?
|
| Cross-Sectional Studies | 13 | 2023 | 2265 | 0.670 |
Why?
|
| Coronary Disease | 4 | 2007 | 358 | 0.670 |
Why?
|
| Nerve Growth Factors | 1 | 2019 | 75 | 0.670 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 3256 | 0.660 |
Why?
|
| Antigen-Antibody Complex | 6 | 2019 | 175 | 0.650 |
Why?
|
| Episode of Care | 1 | 2018 | 12 | 0.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 467 | 0.640 |
Why?
|
| Eye Proteins | 1 | 2019 | 160 | 0.630 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 1533 | 0.630 |
Why?
|
| Health Services | 2 | 2018 | 87 | 0.630 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 41 | 0.620 |
Why?
|
| Prospective Studies | 16 | 2022 | 3703 | 0.610 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2018 | 76 | 0.610 |
Why?
|
| Serpins | 1 | 2019 | 205 | 0.590 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2018 | 127 | 0.590 |
Why?
|
| South Carolina | 11 | 2019 | 2752 | 0.590 |
Why?
|
| Urban Population | 2 | 2018 | 254 | 0.590 |
Why?
|
| Diabetes Complications | 7 | 2017 | 249 | 0.580 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 17 | 0.580 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 28 | 0.580 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2015 | 54 | 0.580 |
Why?
|
| Asthma | 1 | 2020 | 345 | 0.570 |
Why?
|
| Mental Disorders | 4 | 2022 | 659 | 0.560 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 955 | 0.540 |
Why?
|
| Diabetic Retinopathy | 4 | 2019 | 110 | 0.540 |
Why?
|
| Electric Stimulation Therapy | 2 | 2009 | 147 | 0.530 |
Why?
|
| Calcinosis | 4 | 2010 | 241 | 0.530 |
Why?
|
| Carotid Arteries | 4 | 2010 | 110 | 0.520 |
Why?
|
| E-Selectin | 5 | 2017 | 44 | 0.510 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 147 | 0.510 |
Why?
|
| Disabled Persons | 1 | 2015 | 94 | 0.490 |
Why?
|
| Myocardial Infarction | 2 | 2018 | 807 | 0.490 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2022 | 161 | 0.470 |
Why?
|
| Hypoglycemic Agents | 9 | 2016 | 361 | 0.460 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 4843 | 0.460 |
Why?
|
| Arteriosclerosis | 2 | 2003 | 137 | 0.430 |
Why?
|
| Postpartum Period | 2 | 2010 | 67 | 0.430 |
Why?
|
| Survival Rate | 7 | 2021 | 1055 | 0.410 |
Why?
|
| Kidney Transplantation | 6 | 2016 | 839 | 0.410 |
Why?
|
| Parents | 2 | 2022 | 309 | 0.400 |
Why?
|
| Infant, Newborn | 6 | 2022 | 2455 | 0.400 |
Why?
|
| Graft Survival | 5 | 2016 | 465 | 0.390 |
Why?
|
| Telemedicine | 4 | 2022 | 699 | 0.390 |
Why?
|
| Body Weight | 2 | 2013 | 554 | 0.390 |
Why?
|
| Stroke | 2 | 2021 | 2162 | 0.390 |
Why?
|
| Ophthalmology | 3 | 2022 | 39 | 0.380 |
Why?
|
| Adiposity | 2 | 2022 | 88 | 0.380 |
Why?
|
| Spinal Cord Injuries | 2 | 2009 | 551 | 0.380 |
Why?
|
| Prisons | 1 | 2010 | 18 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2013 | 786 | 0.370 |
Why?
|
| Mass Screening | 4 | 2010 | 838 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 467 | 0.370 |
Why?
|
| Texas | 10 | 2013 | 92 | 0.360 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 286 | 0.360 |
Why?
|
| Genome-Wide Association Study | 3 | 2022 | 240 | 0.350 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 581 | 0.340 |
Why?
|
| Glaucoma | 2 | 2019 | 50 | 0.340 |
Why?
|
| Maternal Age | 3 | 2015 | 70 | 0.340 |
Why?
|
| Bicycling | 1 | 2009 | 39 | 0.330 |
Why?
|
| Cerebral Palsy | 1 | 2009 | 24 | 0.330 |
Why?
|
| Food, Fortified | 2 | 2019 | 38 | 0.330 |
Why?
|
| Inflammation | 5 | 2017 | 1030 | 0.330 |
Why?
|
| Personal Satisfaction | 2 | 2020 | 123 | 0.320 |
Why?
|
| Macular Degeneration | 2 | 2019 | 75 | 0.320 |
Why?
|
| Tunica Media | 2 | 2010 | 33 | 0.320 |
Why?
|
| Nutritional Status | 2 | 2020 | 112 | 0.320 |
Why?
|
| Tunica Intima | 2 | 2010 | 59 | 0.320 |
Why?
|
| Sphingolipids | 3 | 2022 | 337 | 0.320 |
Why?
|
| Software | 3 | 2022 | 418 | 0.320 |
Why?
|
| Violence | 1 | 2010 | 275 | 0.320 |
Why?
|
| Genetic Linkage | 2 | 2005 | 90 | 0.320 |
Why?
|
| Cataract | 2 | 2019 | 134 | 0.310 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 4 | 2017 | 58 | 0.310 |
Why?
|
| Glomerular Filtration Rate | 3 | 2019 | 274 | 0.310 |
Why?
|
| Melanoma | 2 | 2022 | 335 | 0.300 |
Why?
|
| Regression Analysis | 5 | 2015 | 737 | 0.300 |
Why?
|
| Receptors, Estrogen | 3 | 2017 | 142 | 0.300 |
Why?
|
| Prediabetic State | 1 | 2008 | 48 | 0.300 |
Why?
|
| Cholesterol | 4 | 2022 | 331 | 0.290 |
Why?
|
| Time Factors | 13 | 2021 | 4655 | 0.290 |
Why?
|
| Brain Injuries | 1 | 2010 | 268 | 0.290 |
Why?
|
| Graft Rejection | 6 | 2016 | 458 | 0.290 |
Why?
|
| Prognosis | 10 | 2019 | 2093 | 0.290 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 375 | 0.290 |
Why?
|
| Kidney Diseases | 2 | 2022 | 307 | 0.290 |
Why?
|
| Exercise Therapy | 1 | 2009 | 183 | 0.290 |
Why?
|
| Receptors, Progesterone | 2 | 2017 | 57 | 0.290 |
Why?
|
| Beverages | 3 | 2019 | 50 | 0.280 |
Why?
|
| Eye Diseases | 2 | 2017 | 38 | 0.280 |
Why?
|
| Dietary Supplements | 2 | 2019 | 331 | 0.280 |
Why?
|
| Models, Statistical | 3 | 2020 | 448 | 0.280 |
Why?
|
| Veterans Health | 2 | 2017 | 62 | 0.270 |
Why?
|
| Kidney Failure, Chronic | 3 | 2016 | 365 | 0.270 |
Why?
|
| Kidney | 4 | 2022 | 945 | 0.270 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 3 | 2017 | 27 | 0.270 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 3 | 2017 | 27 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2005 | 56 | 0.260 |
Why?
|
| Pediatrics | 1 | 2009 | 341 | 0.260 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 1465 | 0.260 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 110 | 0.260 |
Why?
|
| Longitudinal Studies | 8 | 2020 | 1054 | 0.250 |
Why?
|
| Mothers | 3 | 2022 | 172 | 0.240 |
Why?
|
| C-Reactive Protein | 5 | 2017 | 180 | 0.240 |
Why?
|
| Spatial Analysis | 3 | 2021 | 33 | 0.240 |
Why?
|
| Birth Certificates | 2 | 2015 | 16 | 0.240 |
Why?
|
| Renal Insufficiency | 2 | 2016 | 121 | 0.230 |
Why?
|
| Genetic Variation | 3 | 2007 | 220 | 0.230 |
Why?
|
| Hypercholesterolemia | 3 | 2022 | 86 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 4 | 2017 | 104 | 0.230 |
Why?
|
| Interleukin-6 | 5 | 2017 | 330 | 0.230 |
Why?
|
| Sex Distribution | 4 | 2007 | 272 | 0.220 |
Why?
|
| Endothelium, Vascular | 2 | 2015 | 371 | 0.210 |
Why?
|
| Nutritional Requirements | 2 | 2020 | 57 | 0.210 |
Why?
|
| Micronutrients | 2 | 2020 | 31 | 0.210 |
Why?
|
| Delirium | 1 | 2023 | 45 | 0.210 |
Why?
|
| Caffeine | 1 | 2022 | 81 | 0.210 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2002 | 52 | 0.210 |
Why?
|
| Anticholesteremic Agents | 1 | 2022 | 49 | 0.210 |
Why?
|
| Internet | 2 | 2022 | 390 | 0.210 |
Why?
|
| Gestational Age | 2 | 2013 | 389 | 0.200 |
Why?
|
| Autoantibodies | 2 | 2016 | 434 | 0.200 |
Why?
|
| Malondialdehyde | 5 | 2016 | 43 | 0.200 |
Why?
|
| Ultrasonography | 5 | 2010 | 453 | 0.200 |
Why?
|
| Carotid Stenosis | 1 | 2002 | 163 | 0.190 |
Why?
|
| Maternal Mortality | 1 | 2021 | 16 | 0.190 |
Why?
|
| Models, Biological | 3 | 2020 | 981 | 0.190 |
Why?
|
| Microvascular Angina | 1 | 2000 | 2 | 0.190 |
Why?
|
| Length of Stay | 3 | 2023 | 780 | 0.190 |
Why?
|
| Body Composition | 1 | 2021 | 119 | 0.190 |
Why?
|
| Endocrine Disruptors | 1 | 2021 | 31 | 0.190 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 35 | 0.190 |
Why?
|
| Bias | 2 | 2021 | 148 | 0.190 |
Why?
|
| Health Status | 2 | 2019 | 429 | 0.180 |
Why?
|
| Comorbidity | 7 | 2016 | 1425 | 0.180 |
Why?
|
| Geography | 1 | 2020 | 80 | 0.180 |
Why?
|
| Carotid Artery Diseases | 1 | 2001 | 83 | 0.180 |
Why?
|
| Family Health | 1 | 2000 | 83 | 0.180 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 157 | 0.180 |
Why?
|
| Premature Birth | 1 | 2022 | 150 | 0.180 |
Why?
|
| Cause of Death | 1 | 2021 | 241 | 0.180 |
Why?
|
| Food Labeling | 1 | 2020 | 10 | 0.180 |
Why?
|
| Insulin | 7 | 2014 | 617 | 0.180 |
Why?
|
| Kupffer Cells | 3 | 1994 | 75 | 0.180 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 1851 | 0.180 |
Why?
|
| Body Height | 1 | 2020 | 67 | 0.180 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 299 | 0.180 |
Why?
|
| Child Health | 1 | 2019 | 15 | 0.180 |
Why?
|
| Nipples | 1 | 2019 | 5 | 0.170 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 3 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2022 | 627 | 0.170 |
Why?
|
| Term Birth | 1 | 2019 | 12 | 0.170 |
Why?
|
| Dietary Sugars | 1 | 2019 | 7 | 0.170 |
Why?
|
| Nutritive Value | 1 | 2019 | 22 | 0.170 |
Why?
|
| Systems Biology | 1 | 2019 | 25 | 0.170 |
Why?
|
| Infant | 3 | 2019 | 2891 | 0.170 |
Why?
|
| Gene Ontology | 1 | 2019 | 31 | 0.170 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 88 | 0.170 |
Why?
|
| Mastectomy | 1 | 2019 | 56 | 0.170 |
Why?
|
| Kallikreins | 1 | 2020 | 323 | 0.170 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 94 | 0.170 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2017 | 45 | 0.170 |
Why?
|
| Data Mining | 1 | 2019 | 45 | 0.160 |
Why?
|
| Risk Assessment | 8 | 2017 | 2004 | 0.160 |
Why?
|
| Nutritive Sweeteners | 1 | 2018 | 3 | 0.160 |
Why?
|
| Non-Nutritive Sweeteners | 1 | 2018 | 4 | 0.160 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 94 | 0.160 |
Why?
|
| Cotinine | 1 | 2018 | 40 | 0.160 |
Why?
|
| Blood Coagulation | 2 | 2017 | 123 | 0.160 |
Why?
|
| Smoking | 1 | 2006 | 1449 | 0.160 |
Why?
|
| Christianity | 1 | 2018 | 16 | 0.160 |
Why?
|
| Genetic Pleiotropy | 1 | 2018 | 10 | 0.160 |
Why?
|
| Sleep | 1 | 2020 | 263 | 0.150 |
Why?
|
| Databases, Genetic | 1 | 2018 | 52 | 0.150 |
Why?
|
| Confidence Intervals | 2 | 2011 | 242 | 0.150 |
Why?
|
| Lipoproteins | 2 | 2022 | 161 | 0.150 |
Why?
|
| Endpoint Determination | 1 | 2018 | 82 | 0.150 |
Why?
|
| Paraplegia | 2 | 2009 | 28 | 0.150 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 32 | 0.150 |
Why?
|
| Sex Factors | 2 | 2011 | 1265 | 0.150 |
Why?
|
| Advanced Practice Nursing | 1 | 2018 | 36 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2002 | 560 | 0.150 |
Why?
|
| Mitotic Index | 1 | 2017 | 14 | 0.140 |
Why?
|
| Biomedical Technology | 1 | 2017 | 14 | 0.140 |
Why?
|
| No-Show Patients | 1 | 2016 | 9 | 0.140 |
Why?
|
| Androstadienes | 1 | 2017 | 41 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 799 | 0.140 |
Why?
|
| Nitriles | 1 | 2017 | 68 | 0.140 |
Why?
|
| Triazoles | 1 | 2017 | 43 | 0.140 |
Why?
|
| Incidence | 7 | 2016 | 1582 | 0.140 |
Why?
|
| Acute Disease | 1 | 2018 | 658 | 0.140 |
Why?
|
| Referral and Consultation | 4 | 2022 | 383 | 0.140 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 848 | 0.140 |
Why?
|
| Mammography | 1 | 2019 | 310 | 0.140 |
Why?
|
| Leadership | 1 | 2018 | 136 | 0.140 |
Why?
|
| Glycemic Index | 1 | 2016 | 28 | 0.140 |
Why?
|
| Mental Health | 2 | 2019 | 278 | 0.140 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 128 | 0.140 |
Why?
|
| Steroids | 1 | 2016 | 84 | 0.140 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 514 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 109 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 306 | 0.130 |
Why?
|
| Health Care Costs | 2 | 2015 | 346 | 0.130 |
Why?
|
| Hyperlipidemias | 3 | 2012 | 90 | 0.130 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2015 | 6 | 0.130 |
Why?
|
| Transcriptome | 1 | 2017 | 164 | 0.130 |
Why?
|
| Brain Ischemia | 1 | 2001 | 665 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2016 | 109 | 0.130 |
Why?
|
| Polypharmacy | 1 | 2015 | 31 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 2 | 2017 | 329 | 0.130 |
Why?
|
| Propensity Score | 3 | 2021 | 116 | 0.130 |
Why?
|
| Child Behavior Disorders | 1 | 2015 | 69 | 0.120 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 83 | 0.120 |
Why?
|
| Insulin Resistance | 2 | 2014 | 241 | 0.120 |
Why?
|
| Algorithms | 5 | 2022 | 1195 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 79 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2015 | 110 | 0.120 |
Why?
|
| Logistic Models | 5 | 2013 | 1419 | 0.120 |
Why?
|
| Living Donors | 1 | 2016 | 160 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 170 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 1329 | 0.120 |
Why?
|
| Mutation | 1 | 2019 | 1213 | 0.120 |
Why?
|
| Organ Preservation Solutions | 1 | 1994 | 45 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2015 | 384 | 0.120 |
Why?
|
| Phagocytosis | 1 | 1994 | 65 | 0.120 |
Why?
|
| Cholesterol, HDL | 3 | 2014 | 112 | 0.120 |
Why?
|
| Depression | 2 | 2022 | 942 | 0.110 |
Why?
|
| Musculoskeletal Diseases | 1 | 2014 | 45 | 0.110 |
Why?
|
| Apolipoproteins | 1 | 2013 | 51 | 0.110 |
Why?
|
| Haptoglobins | 1 | 2013 | 12 | 0.110 |
Why?
|
| Adenosine | 1 | 1994 | 165 | 0.110 |
Why?
|
| Thiolester Hydrolases | 1 | 2013 | 2 | 0.110 |
Why?
|
| Autism Spectrum Disorder | 1 | 2015 | 111 | 0.110 |
Why?
|
| Psychotic Disorders | 1 | 2014 | 157 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2015 | 267 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2014 | 291 | 0.110 |
Why?
|
| Genotype | 3 | 2021 | 785 | 0.110 |
Why?
|
| Health Surveys | 1 | 2015 | 488 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 244 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2019 | 824 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 142 | 0.110 |
Why?
|
| Physical Therapy Modalities | 1 | 2014 | 133 | 0.110 |
Why?
|
| Delayed Graft Function | 3 | 2016 | 39 | 0.110 |
Why?
|
| Self Report | 1 | 2014 | 370 | 0.110 |
Why?
|
| Age Distribution | 2 | 2003 | 319 | 0.110 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 2 | 2022 | 20 | 0.100 |
Why?
|
| Biometry | 1 | 2012 | 72 | 0.100 |
Why?
|
| Pain Management | 1 | 2014 | 186 | 0.100 |
Why?
|
| Fetal Development | 2 | 2022 | 70 | 0.100 |
Why?
|
| Age Factors | 2 | 2019 | 1860 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1515 | 0.100 |
Why?
|
| Mexico | 1 | 2011 | 38 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 1615 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.100 |
Why?
|
| Georgia | 3 | 2017 | 161 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 161 | 0.100 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 18 | 0.100 |
Why?
|
| Patient Selection | 1 | 2015 | 592 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2013 | 1549 | 0.100 |
Why?
|
| Data Collection | 1 | 2012 | 420 | 0.090 |
Why?
|
| Emigrants and Immigrants | 1 | 2011 | 45 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2011 | 145 | 0.090 |
Why?
|
| Glucose Tolerance Test | 2 | 2008 | 75 | 0.090 |
Why?
|
| Trauma Severity Indices | 1 | 2010 | 80 | 0.090 |
Why?
|
| Immunity, Humoral | 1 | 2010 | 42 | 0.090 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 23 | 0.090 |
Why?
|
| Ceramides | 1 | 2014 | 578 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 292 | 0.090 |
Why?
|
| Haplotypes | 2 | 2007 | 174 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 349 | 0.090 |
Why?
|
| Vaccination | 1 | 2011 | 182 | 0.080 |
Why?
|
| Ocular Hypertension | 2 | 2019 | 43 | 0.080 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2009 | 20 | 0.080 |
Why?
|
| Medicare | 2 | 2022 | 316 | 0.080 |
Why?
|
| Neoplasms | 2 | 2015 | 1664 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 498 | 0.080 |
Why?
|
| Age of Onset | 2 | 2007 | 188 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2015 | 7028 | 0.080 |
Why?
|
| Equipment Failure Analysis | 1 | 2009 | 121 | 0.080 |
Why?
|
| Vitamin D | 1 | 2013 | 516 | 0.080 |
Why?
|
| Abdomen | 1 | 2008 | 80 | 0.080 |
Why?
|
| Qualitative Research | 2 | 2022 | 369 | 0.080 |
Why?
|
| Self Care | 1 | 2011 | 252 | 0.080 |
Why?
|
| Glucose Intolerance | 2 | 2007 | 36 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1070 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2008 | 98 | 0.070 |
Why?
|
| Fasting | 2 | 2006 | 75 | 0.070 |
Why?
|
| Equipment Design | 1 | 2009 | 500 | 0.070 |
Why?
|
| TCF Transcription Factors | 1 | 2007 | 5 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2008 | 221 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 10 | 0.070 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2007 | 28 | 0.070 |
Why?
|
| User-Computer Interface | 2 | 2019 | 230 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 2007 | 83 | 0.070 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2006 | 4 | 0.070 |
Why?
|
| Pedigree | 2 | 2006 | 159 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2007 | 424 | 0.070 |
Why?
|
| Hyperinsulinism | 2 | 2004 | 23 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2077 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2011 | 285 | 0.070 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 33 | 0.070 |
Why?
|
| Sweden | 1 | 2006 | 21 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2006 | 24 | 0.070 |
Why?
|
| Biomedical Engineering | 1 | 2005 | 20 | 0.070 |
Why?
|
| HIV Infections | 1 | 2014 | 775 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2006 | 112 | 0.070 |
Why?
|
| Acetylglucosaminidase | 1 | 2005 | 8 | 0.060 |
Why?
|
| Linkage Disequilibrium | 3 | 2013 | 91 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1753 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2005 | 144 | 0.060 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 57 | 0.060 |
Why?
|
| Acetyltransferases | 1 | 2005 | 49 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 50 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 756 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2005 | 50 | 0.060 |
Why?
|
| Muscle Contraction | 1 | 2005 | 210 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 929 | 0.060 |
Why?
|
| Exercise Test | 1 | 2005 | 242 | 0.060 |
Why?
|
| Europe | 2 | 2021 | 196 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 33 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 378 | 0.060 |
Why?
|
| Oxygen | 1 | 2005 | 386 | 0.060 |
Why?
|
| Carotid Artery, Common | 1 | 2003 | 25 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2004 | 141 | 0.060 |
Why?
|
| Headache | 1 | 2004 | 68 | 0.060 |
Why?
|
| Carotid Artery, Internal | 1 | 2003 | 85 | 0.060 |
Why?
|
| Counseling | 2 | 2022 | 279 | 0.050 |
Why?
|
| Migraine Disorders | 1 | 2004 | 66 | 0.050 |
Why?
|
| Poverty | 2 | 2002 | 218 | 0.050 |
Why?
|
| Apolipoproteins M | 1 | 2022 | 5 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 307 | 0.050 |
Why?
|
| Phenotype | 3 | 2017 | 946 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 536 | 0.050 |
Why?
|
| Halogenated Diphenyl Ethers | 1 | 2022 | 17 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2022 | 45 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 186 | 0.050 |
Why?
|
| Lactosylceramides | 1 | 2022 | 27 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2023 | 86 | 0.050 |
Why?
|
| Immunoglobulin G | 2 | 2016 | 481 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 87 | 0.050 |
Why?
|
| Triglycerides | 2 | 2017 | 184 | 0.050 |
Why?
|
| Africa | 1 | 2021 | 41 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 139 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 96 | 0.050 |
Why?
|
| Alleles | 3 | 2007 | 386 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2010 | 1242 | 0.050 |
Why?
|
| Reference Values | 2 | 2014 | 579 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2012 | 411 | 0.050 |
Why?
|
| Family | 1 | 2002 | 293 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 546 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 265 | 0.050 |
Why?
|
| Demography | 1 | 2001 | 279 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 307 | 0.050 |
Why?
|
| Cytokines | 2 | 2014 | 866 | 0.040 |
Why?
|
| Observer Variation | 1 | 2001 | 330 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2013 | 207 | 0.040 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2019 | 24 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2016 | 621 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 18 | 0.040 |
Why?
|
| Women's Health | 1 | 2000 | 148 | 0.040 |
Why?
|
| Lipids | 2 | 2014 | 298 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2019 | 77 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 30 | 0.040 |
Why?
|
| Publications | 1 | 2019 | 17 | 0.040 |
Why?
|
| Recommended Dietary Allowances | 1 | 2019 | 10 | 0.040 |
Why?
|
| Child Behavior | 1 | 2019 | 56 | 0.040 |
Why?
|
| Vitamin A | 1 | 2020 | 111 | 0.040 |
Why?
|
| Vitamins | 1 | 2020 | 134 | 0.040 |
Why?
|
| Retinal Ganglion Cells | 1 | 2019 | 72 | 0.040 |
Why?
|
| Food Quality | 1 | 2018 | 4 | 0.040 |
Why?
|
| Consumer Product Safety | 1 | 2018 | 32 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 349 | 0.040 |
Why?
|
| Physical Examination | 1 | 2019 | 152 | 0.040 |
Why?
|
| Hyperglycemia | 2 | 2014 | 158 | 0.040 |
Why?
|
| Glycosylation | 1 | 2019 | 185 | 0.040 |
Why?
|
| Nutrition Policy | 1 | 2018 | 44 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2019 | 236 | 0.040 |
Why?
|
| Income | 1 | 2019 | 165 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2022 | 706 | 0.040 |
Why?
|
| Fibrinolysis | 1 | 2017 | 55 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 52 | 0.040 |
Why?
|
| Registries | 2 | 2016 | 730 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2017 | 87 | 0.040 |
Why?
|
| Epirubicin | 1 | 2017 | 4 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2017 | 17 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 125 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 264 | 0.040 |
Why?
|
| Risk | 2 | 2011 | 563 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 36 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2022 | 702 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 129 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2016 | 35 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 47 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 62 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2017 | 132 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 129 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2017 | 130 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2017 | 140 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1046 | 0.030 |
Why?
|
| Oxygen Consumption | 3 | 2009 | 258 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2016 | 104 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 114 | 0.030 |
Why?
|
| World Health Organization | 2 | 2007 | 53 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2017 | 231 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2016 | 127 | 0.030 |
Why?
|
| Epitopes | 1 | 2016 | 146 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1994 | 2083 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 110 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2014 | 32 | 0.030 |
Why?
|
| Retinal Vasculitis | 1 | 2014 | 8 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2015 | 86 | 0.030 |
Why?
|
| Liver Circulation | 1 | 1994 | 40 | 0.030 |
Why?
|
| Role | 1 | 2014 | 25 | 0.030 |
Why?
|
| Cold Temperature | 1 | 1994 | 90 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 714 | 0.030 |
Why?
|
| Leptin | 1 | 2014 | 80 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 101 | 0.030 |
Why?
|
| Raffinose | 1 | 1994 | 28 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 1994 | 25 | 0.030 |
Why?
|
| Allopurinol | 1 | 1994 | 36 | 0.030 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 1994 | 24 | 0.030 |
Why?
|
| Urban Health Services | 1 | 2014 | 24 | 0.030 |
Why?
|
| Tissue Preservation | 1 | 1994 | 44 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2014 | 72 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 144 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2014 | 51 | 0.030 |
Why?
|
| ROC Curve | 2 | 2007 | 392 | 0.030 |
Why?
|
| Hypoxia | 1 | 1994 | 169 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 1994 | 75 | 0.030 |
Why?
|
| Solutions | 1 | 1994 | 115 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 216 | 0.030 |
Why?
|
| Acanthosis Nigricans | 1 | 2013 | 4 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2013 | 16 | 0.030 |
Why?
|
| Abdominal Fat | 1 | 2013 | 8 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2014 | 155 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 201 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2014 | 99 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2013 | 59 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 239 | 0.030 |
Why?
|
| Immunoassay | 1 | 2013 | 64 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 120 | 0.030 |
Why?
|
| Medicaid | 1 | 2015 | 301 | 0.030 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 189 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 219 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 201 | 0.030 |
Why?
|
| Creatinine | 1 | 2013 | 243 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 186 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2012 | 42 | 0.030 |
Why?
|
| Surveys and Questionnaires | 3 | 2007 | 2798 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 212 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 284 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2013 | 172 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 626 | 0.030 |
Why?
|
| Glutathione | 1 | 1994 | 343 | 0.030 |
Why?
|
| Reperfusion Injury | 1 | 1994 | 320 | 0.020 |
Why?
|
| Rats | 3 | 1994 | 5300 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2011 | 14 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2012 | 111 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2011 | 9 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 442 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2011 | 15 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 41 | 0.020 |
Why?
|
| North Carolina | 2 | 2002 | 224 | 0.020 |
Why?
|
| Proteomics | 1 | 2013 | 246 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 191 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 159 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 99 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 442 | 0.020 |
Why?
|
| Genomics | 1 | 2011 | 168 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 682 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2011 | 281 | 0.020 |
Why?
|
| Forecasting | 1 | 2011 | 277 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 320 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2012 | 384 | 0.020 |
Why?
|
| Ergometry | 1 | 2009 | 4 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 648 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 1745 | 0.020 |
Why?
|
| Pulmonary Ventilation | 1 | 2009 | 28 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2008 | 29 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 332 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2008 | 29 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2008 | 36 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2007 | 6 | 0.020 |
Why?
|
| Introns | 1 | 2007 | 68 | 0.020 |
Why?
|
| Body Size | 1 | 2007 | 39 | 0.020 |
Why?
|
| Exons | 1 | 2007 | 122 | 0.020 |
Why?
|
| Heart Rate | 1 | 2009 | 568 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2006 | 56 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2008 | 295 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 521 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 137 | 0.020 |
Why?
|
| DNA Primers | 1 | 2006 | 302 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2005 | 13 | 0.020 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 2005 | 10 | 0.020 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2005 | 43 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2010 | 866 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 614 | 0.020 |
Why?
|
| National Health Programs | 1 | 2004 | 11 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2004 | 95 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 132 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2004 | 106 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2007 | 403 | 0.010 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2003 | 4 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 1082 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2003 | 14 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 2003 | 10 | 0.010 |
Why?
|
| Gadolinium | 2 | 1994 | 88 | 0.010 |
Why?
|
| Adult Children | 1 | 2003 | 7 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2003 | 20 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2003 | 35 | 0.010 |
Why?
|
| Genome, Human | 1 | 2003 | 62 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 188 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2002 | 24 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2002 | 24 | 0.010 |
Why?
|
| Body Constitution | 1 | 2002 | 24 | 0.010 |
Why?
|
| Anthropometry | 1 | 2002 | 64 | 0.010 |
Why?
|
| Animals | 3 | 1994 | 20880 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 80 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2324 | 0.010 |
Why?
|
| Life Style | 1 | 2002 | 338 | 0.010 |
Why?
|
| Liver | 2 | 1994 | 1118 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2002 | 497 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2000 | 652 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1994 | 67 | 0.010 |
Why?
|
| Organ Preservation | 1 | 1994 | 69 | 0.010 |
Why?
|
| Reperfusion | 1 | 1994 | 78 | 0.010 |
Why?
|
| Indomethacin | 1 | 1994 | 107 | 0.010 |
Why?
|
| Perfusion | 1 | 1994 | 131 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1994 | 765 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1994 | 567 | 0.010 |
Why?
|